ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Drugs for Treating Hyperuricemia Market Research Report 2026
Published Date: 2026-02-11
|
Report Code: QYRE-Auto-10D18147
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Drugs for Treating Hyperuricemia Market Research Report 2024
BUY CHAPTERS

Global Drugs for Treating Hyperuricemia Market Research Report 2026

Code: QYRE-Auto-10D18147
Report
2026-02-11
Pages:125
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
TEVA
Mylan Pharmaceuticals
Takeda Pharmaceuticals
Sanwa Kagaku Kenkyusho
Towa Pharmaceutical
TOA Eiyo
Astrazeneca plc
Mochida Pharmaceutical
Lannett Company
Horizo​​n Therapeutics
Sanofi
GSK
Fuji yakuhin

Drugs for Treating Hyperuricemia Market

The global Drugs for Treating Hyperuricemia market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Drugs for Treating Hyperuricemia competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Drugs used to treat hyperuricemia,a condition characterized by elevated levels of uric acid in the blood,primarily aim to lower uric acid levels to prevent complications such as gout and kidney stones.The most common medications include xanthine oxidase inhibitors like allopurinol and febuxostat,which reduce uric acid production by inhibiting the enzyme responsible for its formation.Another class,uricosuric agents such as probenecid,work by increasing uric acid excretion through the kidneys.
The North American market for Drugs for Treating Hyperuricemia is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Drugs for Treating Hyperuricemia is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Drugs for Treating Hyperuricemia include Teva, Mylan Pharmaceuticals, Takeda Pharmaceuticals, Sanwa Kagaku Kenkyusho, Towa Pharmaceutical, Toa Eiyo, AstraZeneca, Mochida Pharmaceutical, Lannett Company, Horizo​​n Therapeutics, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Drugs for Treating Hyperuricemia market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Drugs for Treating Hyperuricemia. The Drugs for Treating Hyperuricemia market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Drugs for Treating Hyperuricemia market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Drugs for Treating Hyperuricemia manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Drugs for Treating Hyperuricemia Market Report

Report Metric Details
Report Name Drugs for Treating Hyperuricemia Market
Segment by Type
  • Uric Acid Production Inhibitors
  • Urate-stimulating Excretion Agents
  • Other
by Application
  • Hospitals and Clinics
  • Retail Pharmacies
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Teva, Mylan Pharmaceuticals, Takeda Pharmaceuticals, Sanwa Kagaku Kenkyusho, Towa Pharmaceutical, Toa Eiyo, AstraZeneca, Mochida Pharmaceutical, Lannett Company, Horizo​​n Therapeutics, Sanofi, GSK, Fuji Yakuhin
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Drugs for Treating Hyperuricemia manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Drugs for Treating Hyperuricemia sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Drugs for Treating Hyperuricemia Market report?

Ans: The main players in the Drugs for Treating Hyperuricemia Market are Teva, Mylan Pharmaceuticals, Takeda Pharmaceuticals, Sanwa Kagaku Kenkyusho, Towa Pharmaceutical, Toa Eiyo, AstraZeneca, Mochida Pharmaceutical, Lannett Company, Horizo​​n Therapeutics, Sanofi, GSK, Fuji Yakuhin

What are the Application segmentation covered in the Drugs for Treating Hyperuricemia Market report?

Ans: The Applications covered in the Drugs for Treating Hyperuricemia Market report are Hospitals and Clinics, Retail Pharmacies, Other

What are the Type segmentation covered in the Drugs for Treating Hyperuricemia Market report?

Ans: The Types covered in the Drugs for Treating Hyperuricemia Market report are Uric Acid Production Inhibitors, Urate-stimulating Excretion Agents, Other

1 Drugs for Treating Hyperuricemia Market Overview
1.1 Product Definition
1.2 Drugs for Treating Hyperuricemia by Type
1.2.1 Global Drugs for Treating Hyperuricemia Market Value by Type: 2025 vs 2032
1.2.2 Uric Acid Production Inhibitors
1.2.3 Urate-stimulating Excretion Agents
1.2.4 Other
1.3 Drugs for Treating Hyperuricemia by Application
1.3.1 Global Drugs for Treating Hyperuricemia Market Value by Application: 2025 vs 2032
1.3.2 Hospitals and Clinics
1.3.3 Retail Pharmacies
1.3.4 Other
1.4 Global Drugs for Treating Hyperuricemia Market Size Estimates and Forecasts
1.4.1 Global Drugs for Treating Hyperuricemia Revenue 2021–2032
1.4.2 Global Drugs for Treating Hyperuricemia Sales 2021–2032
1.4.3 Global Drugs for Treating Hyperuricemia Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Drugs for Treating Hyperuricemia Market Competition by Manufacturers
2.1 Global Drugs for Treating Hyperuricemia Sales Market Share by Manufacturers (2021–2026)
2.2 Global Drugs for Treating Hyperuricemia Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Drugs for Treating Hyperuricemia Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Drugs for Treating Hyperuricemia, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Drugs for Treating Hyperuricemia, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Drugs for Treating Hyperuricemia, Product Types and Applications
2.7 Global Key Manufacturers of Drugs for Treating Hyperuricemia, Date of Entry into the Industry
2.8 Global Drugs for Treating Hyperuricemia Market Competitive Situation and Trends
2.8.1 Global Drugs for Treating Hyperuricemia Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Drugs for Treating Hyperuricemia Players Market Share by Revenue
2.8.3 Global Drugs for Treating Hyperuricemia Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Drugs for Treating Hyperuricemia Market Scenario by Region
3.1 Global Drugs for Treating Hyperuricemia Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Drugs for Treating Hyperuricemia Sales by Region: 2021–2032
3.2.1 Global Drugs for Treating Hyperuricemia Sales by Region: 2021–2026
3.2.2 Global Drugs for Treating Hyperuricemia Sales by Region: 2027–2032
3.3 Global Drugs for Treating Hyperuricemia Revenue by Region: 2021–2032
3.3.1 Global Drugs for Treating Hyperuricemia Revenue by Region: 2021–2026
3.3.2 Global Drugs for Treating Hyperuricemia Revenue by Region: 2027–2032
3.4 North America Drugs for Treating Hyperuricemia Market Facts & Figures by Country
3.4.1 North America Drugs for Treating Hyperuricemia Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Drugs for Treating Hyperuricemia Sales by Country (2021–2032)
3.4.3 North America Drugs for Treating Hyperuricemia Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Drugs for Treating Hyperuricemia Market Facts & Figures by Country
3.5.1 Europe Drugs for Treating Hyperuricemia Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Drugs for Treating Hyperuricemia Sales by Country (2021–2032)
3.5.3 Europe Drugs for Treating Hyperuricemia Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Drugs for Treating Hyperuricemia Market Facts & Figures by Region
3.6.1 Asia Pacific Drugs for Treating Hyperuricemia Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Drugs for Treating Hyperuricemia Sales by Region (2021–2032)
3.6.3 Asia Pacific Drugs for Treating Hyperuricemia Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Drugs for Treating Hyperuricemia Market Facts & Figures by Country
3.7.1 Latin America Drugs for Treating Hyperuricemia Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Drugs for Treating Hyperuricemia Sales by Country (2021–2032)
3.7.3 Latin America Drugs for Treating Hyperuricemia Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Drugs for Treating Hyperuricemia Market Facts & Figures by Country
3.8.1 Middle East and Africa Drugs for Treating Hyperuricemia Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Drugs for Treating Hyperuricemia Sales by Country (2021–2032)
3.8.3 Middle East and Africa Drugs for Treating Hyperuricemia Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Drugs for Treating Hyperuricemia Sales by Type (2021–2032)
4.1.1 Global Drugs for Treating Hyperuricemia Sales by Type (2021–2026)
4.1.2 Global Drugs for Treating Hyperuricemia Sales by Type (2027–2032)
4.1.3 Global Drugs for Treating Hyperuricemia Sales Market Share by Type (2021–2032)
4.2 Global Drugs for Treating Hyperuricemia Revenue by Type (2021–2032)
4.2.1 Global Drugs for Treating Hyperuricemia Revenue by Type (2021–2026)
4.2.2 Global Drugs for Treating Hyperuricemia Revenue by Type (2027–2032)
4.2.3 Global Drugs for Treating Hyperuricemia Revenue Market Share by Type (2021–2032)
4.3 Global Drugs for Treating Hyperuricemia Price by Type (2021–2032)
5 Segment by Application
5.1 Global Drugs for Treating Hyperuricemia Sales by Application (2021–2032)
5.1.1 Global Drugs for Treating Hyperuricemia Sales by Application (2021–2026)
5.1.2 Global Drugs for Treating Hyperuricemia Sales by Application (2027–2032)
5.1.3 Global Drugs for Treating Hyperuricemia Sales Market Share by Application (2021–2032)
5.2 Global Drugs for Treating Hyperuricemia Revenue by Application (2021–2032)
5.2.1 Global Drugs for Treating Hyperuricemia Revenue by Application (2021–2026)
5.2.2 Global Drugs for Treating Hyperuricemia Revenue by Application (2027–2032)
5.2.3 Global Drugs for Treating Hyperuricemia Revenue Market Share by Application (2021–2032)
5.3 Global Drugs for Treating Hyperuricemia Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Teva
6.1.1 Teva Company Information
6.1.2 Teva Description and Business Overview
6.1.3 Teva Drugs for Treating Hyperuricemia Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Teva Drugs for Treating Hyperuricemia Product Portfolio
6.1.5 Teva Recent Developments/Updates
6.2 Mylan Pharmaceuticals
6.2.1 Mylan Pharmaceuticals Company Information
6.2.2 Mylan Pharmaceuticals Description and Business Overview
6.2.3 Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Product Portfolio
6.2.5 Mylan Pharmaceuticals Recent Developments/Updates
6.3 Takeda Pharmaceuticals
6.3.1 Takeda Pharmaceuticals Company Information
6.3.2 Takeda Pharmaceuticals Description and Business Overview
6.3.3 Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Product Portfolio
6.3.5 Takeda Pharmaceuticals Recent Developments/Updates
6.4 Sanwa Kagaku Kenkyusho
6.4.1 Sanwa Kagaku Kenkyusho Company Information
6.4.2 Sanwa Kagaku Kenkyusho Description and Business Overview
6.4.3 Sanwa Kagaku Kenkyusho Drugs for Treating Hyperuricemia Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Sanwa Kagaku Kenkyusho Drugs for Treating Hyperuricemia Product Portfolio
6.4.5 Sanwa Kagaku Kenkyusho Recent Developments/Updates
6.5 Towa Pharmaceutical
6.5.1 Towa Pharmaceutical Company Information
6.5.2 Towa Pharmaceutical Description and Business Overview
6.5.3 Towa Pharmaceutical Drugs for Treating Hyperuricemia Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Towa Pharmaceutical Drugs for Treating Hyperuricemia Product Portfolio
6.5.5 Towa Pharmaceutical Recent Developments/Updates
6.6 Toa Eiyo
6.6.1 Toa Eiyo Company Information
6.6.2 Toa Eiyo Description and Business Overview
6.6.3 Toa Eiyo Drugs for Treating Hyperuricemia Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Toa Eiyo Drugs for Treating Hyperuricemia Product Portfolio
6.6.5 Toa Eiyo Recent Developments/Updates
6.7 AstraZeneca
6.7.1 AstraZeneca Company Information
6.7.2 AstraZeneca Description and Business Overview
6.7.3 AstraZeneca Drugs for Treating Hyperuricemia Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 AstraZeneca Drugs for Treating Hyperuricemia Product Portfolio
6.7.5 AstraZeneca Recent Developments/Updates
6.8 Mochida Pharmaceutical
6.8.1 Mochida Pharmaceutical Company Information
6.8.2 Mochida Pharmaceutical Description and Business Overview
6.8.3 Mochida Pharmaceutical Drugs for Treating Hyperuricemia Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Mochida Pharmaceutical Drugs for Treating Hyperuricemia Product Portfolio
6.8.5 Mochida Pharmaceutical Recent Developments/Updates
6.9 Lannett Company
6.9.1 Lannett Company Company Information
6.9.2 Lannett Company Description and Business Overview
6.9.3 Lannett Company Drugs for Treating Hyperuricemia Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Lannett Company Drugs for Treating Hyperuricemia Product Portfolio
6.9.5 Lannett Company Recent Developments/Updates
6.10 Horizo​​n Therapeutics
6.10.1 Horizo​​n Therapeutics Company Information
6.10.2 Horizo​​n Therapeutics Description and Business Overview
6.10.3 Horizo​​n Therapeutics Drugs for Treating Hyperuricemia Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Horizo​​n Therapeutics Drugs for Treating Hyperuricemia Product Portfolio
6.10.5 Horizo​​n Therapeutics Recent Developments/Updates
6.11 Sanofi
6.11.1 Sanofi Company Information
6.11.2 Sanofi Description and Business Overview
6.11.3 Sanofi Drugs for Treating Hyperuricemia Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Sanofi Drugs for Treating Hyperuricemia Product Portfolio
6.11.5 Sanofi Recent Developments/Updates
6.12 GSK
6.12.1 GSK Company Information
6.12.2 GSK Description and Business Overview
6.12.3 GSK Drugs for Treating Hyperuricemia Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 GSK Drugs for Treating Hyperuricemia Product Portfolio
6.12.5 GSK Recent Developments/Updates
6.13 Fuji Yakuhin
6.13.1 Fuji Yakuhin Company Information
6.13.2 Fuji Yakuhin Description and Business Overview
6.13.3 Fuji Yakuhin Drugs for Treating Hyperuricemia Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Fuji Yakuhin Drugs for Treating Hyperuricemia Product Portfolio
6.13.5 Fuji Yakuhin Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Drugs for Treating Hyperuricemia Industry Chain Analysis
7.2 Drugs for Treating Hyperuricemia Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Drugs for Treating Hyperuricemia Production Mode & Process Analysis
7.4 Drugs for Treating Hyperuricemia Sales and Marketing
7.4.1 Drugs for Treating Hyperuricemia Sales Channels
7.4.2 Drugs for Treating Hyperuricemia Distributors
7.5 Drugs for Treating Hyperuricemia Customer Analysis
8 Drugs for Treating Hyperuricemia Market Dynamics
8.1 Drugs for Treating Hyperuricemia Industry Trends
8.2 Drugs for Treating Hyperuricemia Market Drivers
8.3 Drugs for Treating Hyperuricemia Market Challenges
8.4 Drugs for Treating Hyperuricemia Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
TEVA
Mylan Pharmaceuticals
Takeda Pharmaceuticals
Sanwa Kagaku Kenkyusho
Towa Pharmaceutical
TOA Eiyo
Astrazeneca plc
Mochida Pharmaceutical
Lannett Company
Horizo​​n Therapeutics
Sanofi
GSK
Fuji yakuhin
List of Tables
 Table 1. Global Drugs for Treating Hyperuricemia Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Drugs for Treating Hyperuricemia Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Drugs for Treating Hyperuricemia Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Drugs for Treating Hyperuricemia Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global Drugs for Treating Hyperuricemia Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Drugs for Treating Hyperuricemia Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Drugs for Treating Hyperuricemia Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Drugs for Treating Hyperuricemia Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Drugs for Treating Hyperuricemia, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Drugs for Treating Hyperuricemia, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Drugs for Treating Hyperuricemia, Product Types and Applications
 Table 12. Global Key Manufacturers of Drugs for Treating Hyperuricemia, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Drugs for Treating Hyperuricemia Companies by Tier (Tier 1, Tier 2, Tier 3), based on Drugs for Treating Hyperuricemia Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Drugs for Treating Hyperuricemia Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Drugs for Treating Hyperuricemia Sales by Region (K Units), 2021–2026
 Table 18. Global Drugs for Treating Hyperuricemia Sales Market Share by Region (2021–2026)
 Table 19. Global Drugs for Treating Hyperuricemia Sales by Region (K Units), 2027–2032
 Table 20. Global Drugs for Treating Hyperuricemia Sales Market Share by Region (2027–2032)
 Table 21. Global Drugs for Treating Hyperuricemia Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Drugs for Treating Hyperuricemia Revenue Market Share by Region (2021–2026)
 Table 23. Global Drugs for Treating Hyperuricemia Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Drugs for Treating Hyperuricemia Revenue Market Share by Region (2027–2032)
 Table 25. North America Drugs for Treating Hyperuricemia Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Drugs for Treating Hyperuricemia Sales by Country (K Units), 2021–2026
 Table 27. North America Drugs for Treating Hyperuricemia Sales by Country (K Units), 2027–2032
 Table 28. North America Drugs for Treating Hyperuricemia Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Drugs for Treating Hyperuricemia Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Drugs for Treating Hyperuricemia Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Drugs for Treating Hyperuricemia Sales by Country (K Units), 2021–2026
 Table 32. Europe Drugs for Treating Hyperuricemia Sales by Country (K Units), 2027–2032
 Table 33. Europe Drugs for Treating Hyperuricemia Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Drugs for Treating Hyperuricemia Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Drugs for Treating Hyperuricemia Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Drugs for Treating Hyperuricemia Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific Drugs for Treating Hyperuricemia Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific Drugs for Treating Hyperuricemia Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Drugs for Treating Hyperuricemia Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Drugs for Treating Hyperuricemia Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Drugs for Treating Hyperuricemia Sales by Country (K Units), 2021–2026
 Table 42. Latin America Drugs for Treating Hyperuricemia Sales by Country (K Units), 2027–2032
 Table 43. Latin America Drugs for Treating Hyperuricemia Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Drugs for Treating Hyperuricemia Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Drugs for Treating Hyperuricemia Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Drugs for Treating Hyperuricemia Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa Drugs for Treating Hyperuricemia Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa Drugs for Treating Hyperuricemia Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Drugs for Treating Hyperuricemia Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Drugs for Treating Hyperuricemia Sales (K Units) by Type (2021–2026)
 Table 51. Global Drugs for Treating Hyperuricemia Sales (K Units) by Type (2027–2032)
 Table 52. Global Drugs for Treating Hyperuricemia Sales Market Share by Type (2021–2026)
 Table 53. Global Drugs for Treating Hyperuricemia Sales Market Share by Type (2027–2032)
 Table 54. Global Drugs for Treating Hyperuricemia Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Drugs for Treating Hyperuricemia Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Drugs for Treating Hyperuricemia Revenue Market Share by Type (2021–2026)
 Table 57. Global Drugs for Treating Hyperuricemia Revenue Market Share by Type (2027–2032)
 Table 58. Global Drugs for Treating Hyperuricemia Price (US$/Unit) by Type (2021–2026)
 Table 59. Global Drugs for Treating Hyperuricemia Price (US$/Unit) by Type (2027–2032)
 Table 60. Global Drugs for Treating Hyperuricemia Sales (K Units) by Application (2021–2026)
 Table 61. Global Drugs for Treating Hyperuricemia Sales (K Units) by Application (2027–2032)
 Table 62. Global Drugs for Treating Hyperuricemia Sales Market Share by Application (2021–2026)
 Table 63. Global Drugs for Treating Hyperuricemia Sales Market Share by Application (2027–2032)
 Table 64. Global Drugs for Treating Hyperuricemia Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Drugs for Treating Hyperuricemia Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Drugs for Treating Hyperuricemia Revenue Market Share by Application (2021–2026)
 Table 67. Global Drugs for Treating Hyperuricemia Revenue Market Share by Application (2027–2032)
 Table 68. Global Drugs for Treating Hyperuricemia Price (US$/Unit) by Application (2021–2026)
 Table 69. Global Drugs for Treating Hyperuricemia Price (US$/Unit) by Application (2027–2032)
 Table 70. Teva Company Information
 Table 71. Teva Description and Business Overview
 Table 72. Teva Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. Teva Drugs for Treating Hyperuricemia Product
 Table 74. Teva Recent Developments/Updates
 Table 75. Mylan Pharmaceuticals Company Information
 Table 76. Mylan Pharmaceuticals Description and Business Overview
 Table 77. Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Product
 Table 79. Mylan Pharmaceuticals Recent Developments/Updates
 Table 80. Takeda Pharmaceuticals Company Information
 Table 81. Takeda Pharmaceuticals Description and Business Overview
 Table 82. Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 83. Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Product
 Table 84. Takeda Pharmaceuticals Recent Developments/Updates
 Table 85. Sanwa Kagaku Kenkyusho Company Information
 Table 86. Sanwa Kagaku Kenkyusho Description and Business Overview
 Table 87. Sanwa Kagaku Kenkyusho Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 88. Sanwa Kagaku Kenkyusho Drugs for Treating Hyperuricemia Product
 Table 89. Sanwa Kagaku Kenkyusho Recent Developments/Updates
 Table 90. Towa Pharmaceutical Company Information
 Table 91. Towa Pharmaceutical Description and Business Overview
 Table 92. Towa Pharmaceutical Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 93. Towa Pharmaceutical Drugs for Treating Hyperuricemia Product
 Table 94. Towa Pharmaceutical Recent Developments/Updates
 Table 95. Toa Eiyo Company Information
 Table 96. Toa Eiyo Description and Business Overview
 Table 97. Toa Eiyo Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 98. Toa Eiyo Drugs for Treating Hyperuricemia Product
 Table 99. Toa Eiyo Recent Developments/Updates
 Table 100. AstraZeneca Company Information
 Table 101. AstraZeneca Description and Business Overview
 Table 102. AstraZeneca Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 103. AstraZeneca Drugs for Treating Hyperuricemia Product
 Table 104. AstraZeneca Recent Developments/Updates
 Table 105. Mochida Pharmaceutical Company Information
 Table 106. Mochida Pharmaceutical Description and Business Overview
 Table 107. Mochida Pharmaceutical Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 108. Mochida Pharmaceutical Drugs for Treating Hyperuricemia Product
 Table 109. Mochida Pharmaceutical Recent Developments/Updates
 Table 110. Lannett Company Company Information
 Table 111. Lannett Company Description and Business Overview
 Table 112. Lannett Company Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 113. Lannett Company Drugs for Treating Hyperuricemia Product
 Table 114. Lannett Company Recent Developments/Updates
 Table 115. Horizo​​n Therapeutics Company Information
 Table 116. Horizo​​n Therapeutics Description and Business Overview
 Table 117. Horizo​​n Therapeutics Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 118. Horizo​​n Therapeutics Drugs for Treating Hyperuricemia Product
 Table 119. Horizo​​n Therapeutics Recent Developments/Updates
 Table 120. Sanofi Company Information
 Table 121. Sanofi Description and Business Overview
 Table 122. Sanofi Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 123. Sanofi Drugs for Treating Hyperuricemia Product
 Table 124. Sanofi Recent Developments/Updates
 Table 125. GSK Company Information
 Table 126. GSK Description and Business Overview
 Table 127. GSK Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 128. GSK Drugs for Treating Hyperuricemia Product
 Table 129. GSK Recent Developments/Updates
 Table 130. Fuji Yakuhin Company Information
 Table 131. Fuji Yakuhin Description and Business Overview
 Table 132. Fuji Yakuhin Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 133. Fuji Yakuhin Drugs for Treating Hyperuricemia Product
 Table 134. Fuji Yakuhin Recent Developments/Updates
 Table 135. Key Raw Materials Lists
 Table 136. Raw Materials Key Suppliers Lists
 Table 137. Drugs for Treating Hyperuricemia Distributors List
 Table 138. Drugs for Treating Hyperuricemia Customers List
 Table 139. Drugs for Treating Hyperuricemia Market Trends
 Table 140. Drugs for Treating Hyperuricemia Market Drivers
 Table 141. Drugs for Treating Hyperuricemia Market Challenges
 Table 142. Drugs for Treating Hyperuricemia Market Restraints
 Table 143. Research Programs/Design for This Report
 Table 144. Key Data Information from Secondary Sources
 Table 145. Key Data Information from Primary Sources
 Table 146. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Drugs for Treating Hyperuricemia
 Figure 2. Global Drugs for Treating Hyperuricemia Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Drugs for Treating Hyperuricemia Market Share by Type: 2025 & 2032
 Figure 4. Uric Acid Production Inhibitors Product Picture
 Figure 5. Urate-stimulating Excretion Agents Product Picture
 Figure 6. Other Product Picture
 Figure 7. Global Drugs for Treating Hyperuricemia Market Value by Application (US$ Million), 2021–2032
 Figure 8. Global Drugs for Treating Hyperuricemia Market Share by Application: 2025 & 2032
 Figure 9. Hospitals and Clinics
 Figure 10. Retail Pharmacies
 Figure 11. Other
 Figure 12. Global Drugs for Treating Hyperuricemia Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 13. Global Drugs for Treating Hyperuricemia Market Size (US$ Million), 2021–2032
 Figure 14. Global Drugs for Treating Hyperuricemia Sales (K Units), 2021–2032
 Figure 15. Global Drugs for Treating Hyperuricemia Average Price (US$/Unit), 2021–2032
 Figure 16. Drugs for Treating Hyperuricemia Report Years Considered
 Figure 17. Drugs for Treating Hyperuricemia Sales Share by Manufacturers in 2025
 Figure 18. Global Drugs for Treating Hyperuricemia Revenue Share by Manufacturers in 2025
 Figure 19. Top 5 and Top 10 Global Drugs for Treating Hyperuricemia Players: Market Share by Revenue in Drugs for Treating Hyperuricemia in 2025
 Figure 20. Drugs for Treating Hyperuricemia Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 21. Global Drugs for Treating Hyperuricemia Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 22. North America Drugs for Treating Hyperuricemia Sales Market Share by Country (2021–2032)
 Figure 23. North America Drugs for Treating Hyperuricemia Revenue Market Share by Country (2021–2032)
 Figure 24. United States Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 25. Canada Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 26. Europe Drugs for Treating Hyperuricemia Sales Market Share by Country (2021–2032)
 Figure 27. Europe Drugs for Treating Hyperuricemia Revenue Market Share by Country (2021–2032)
 Figure 28. Germany Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. France Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. U.K. Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Italy Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. Russia Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 33. Asia Pacific Drugs for Treating Hyperuricemia Sales Market Share by Region (2021–2032)
 Figure 34. Asia Pacific Drugs for Treating Hyperuricemia Revenue Market Share by Region (2021–2032)
 Figure 35. China Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. Japan Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. South Korea Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. India Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. Australia Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. China Taiwan Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Southeast Asia Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. Latin America Drugs for Treating Hyperuricemia Sales Market Share by Country (2021–2032)
 Figure 43. Latin America Drugs for Treating Hyperuricemia Revenue Market Share by Country (2021–2032)
 Figure 44. Mexico Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Brazil Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Argentina Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Colombia Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. Middle East and Africa Drugs for Treating Hyperuricemia Sales Market Share by Country (2021–2032)
 Figure 49. Middle East and Africa Drugs for Treating Hyperuricemia Revenue Market Share by Country (2021–2032)
 Figure 50. Turkey Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. Saudi Arabia Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. UAE Drugs for Treating Hyperuricemia Revenue Growth Rate (US$ Million), 2021–2032
 Figure 53. Global Sales Market Share of Drugs for Treating Hyperuricemia by Type (2021–2032)
 Figure 54. Global Revenue Market Share of Drugs for Treating Hyperuricemia by Type (2021–2032)
 Figure 55. Global Drugs for Treating Hyperuricemia Price (US$/Unit) by Type (2021–2032)
 Figure 56. Global Sales Market Share of Drugs for Treating Hyperuricemia by Application (2021–2032)
 Figure 57. Global Revenue Market Share of Drugs for Treating Hyperuricemia by Application (2021–2032)
 Figure 58. Global Drugs for Treating Hyperuricemia Price (US$/Unit) by Application (2021–2032)
 Figure 59. Drugs for Treating Hyperuricemia Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Global Uric Acid lowering Drugs Market Research Report 2024
Global Xanthine Oxidase Inhibitors for the Treatment of Hyperuricemia Market Research Report 2024
Global Uric Acid Production Inhibitors Market Research Report 2024
Global Topiroxostat Tablets Market Research Report 2024
Global Dotinurad Tablets Market Research Report 2024
Global Probenecid Tablets Market Research Report 2024
Global Febuxostat API Market Research Report 2024
Global Urate stimulating Excretion Agents Market Research Report 2024
Global Hyperuricemia Micromolecular Drugs Market Research Report 2024
Global Chronic Gout Treatment Drug Market Research Report 2024
Antihyperuricemic Agents Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Drugs for the Treatment of Refractory Gout Market Research Report 2024
Uric Acid Health Supplement Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Uric Acid Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Benzbromarone Tablets Market Research Report 2024
Drugs for Amino Acid Metabolism Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Uric Acid Analyzer Market Research Report 2024
Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Research Report 2024
Amino Acid Metabolism Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ursodeoxycholic Acid Drug Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions